|Bid||14.23 x 800|
|Ask||14.24 x 900|
|Day's range||14.21 - 14.41|
|52-week range||10.03 - 20.54|
|Beta (5Y monthly)||1.51|
|PE ratio (TTM)||4.25|
|Earnings date||03 Feb 2020 - 09 Feb 2020|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||07 Sep 2015|
|1y target est||13.50|
Acceleron (XLRN) signs a collaboration/license pact with Fulcrum Therapeutics aimed at identifying small molecules designed to modulate specific pathways targeting a pulmonary disease indication.
Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases
BeiGene's (BGNE) tislelizumab gets an NMPA nod in China for treating patients with classical Hodgkin's lymphoma, having received minimum two prior therapies.
Epizyme (EPZM) gets favorable votes from the FDA's ODAC for tazemetostat in patients with metastatic or locally advanced epithelioid sarcoma not eligible for curative surgery.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Mallinckrodt (MNK) initiates phase IV, multi-center, multiple-dose, open-label study to assess the effects of lead drug Acthar Gel as a therapy option in patients with severe keratitis.
Horizon Therapeutics' (HZNP) pipeline candidate, teprotumumab, gets favorable vote from DODAC of the FDA for the treatment of Thyroid Eye Disease.
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
The FDA assigns a Fast Track status to VistaGen's (VTGN) neuroactive nasal spray PH94B for the on-demand treatment of social anxiety disorder. Stock surges.
TG Therapeutics (TGTX) announces positive first clinical data from its once daily, oral, BTK inhibitor, TG-1701, as a single agent and as a triple therapy in combination.
Regeneron (REGN) reports initial data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma.
Ra Pharmaceuticals (RARX) begins dosing of the first patient in its phase II study of zilucoplan for the treatment of immune-mediated necrotizing myopathy.